Rapid and Sustained Allogeneic Transplantation Using Immunoselected CD34+-Selected Peripheral Blood
Progenitor Cells Mobilized By Recombinant Granulocyte-and Granulocyte-Macrophage
Colony-Stimulating Factors

To the Editor:
We have previously shown in normal donors that administration of either recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) (Immunex, Seattle, WA) at 10 pg/kg/d, or granulocyte colony-stimulating factor (G-CSF) (Amgen, Thousand Oaks, CA) at 10 pg/kg/d, or a combination of G-CSF and GM-CSF at 5 pg/kg/d each, administered subcutaneously for 4 days and followed by leukapheresis on day 5 will enable mobilization and collection of sufficient hematopoietic progenitor cells to perform allogeneic transplantation. ' We also showed that these cells can then be selectively enriched by immunoselection of CD34' progenitors by affinity labeling using dynal paramagnetic microspheres (Baxter IsolexTM 300 System; Baxter Healthcare Corp, Immunotherapy Division, Irvine, CA)' and that the positive selection technique would remove up to 3 logs of T cells, which might be sufficient to reduce the incidence and seventy of acute graft-versus-host disease (GVHD). We have successfully used this methodology to obtain 
CASE REPORTS
Patients were conditioned with high-dose cyclophosphamide (120 mgkg administered over 2 days) and fractionated total body irradiation (total dose, 14 Gy, hyperfractionated over 4 days in 2 Gy fractions). Cyclosporine (Sandoz, East Hanover, NJ) was given in standard dose commencing at 2 mgkg intravenously every 12 hours before transplant from day -4 and adjusted to maintain therapeutic blood levels as prophylaxis against GVHD. G-CSF 5 pgAtg/d was administered subcutaneously from day 1 posttransplant to accelerate granulocyte recovery. Donor A initially failed to mobilize adequately with G-CSF (10 pg/kg/d for 5 days before and daily during apheresis) alone; consequently, G-CSF and GM-CSF were administered sequentially for mobilization of both donors. GM-CSF (10 pg/kg/d subcutaneously) was given for 3 days followed by G-CSF (10 pgl kg/d subcutaneously) for the next 2 days, after which time apheresis was started (day 5). G-CSF was continued until the day before the final apheresis. Peripheral blood progenitor cell (PBPC) collection characteristics and CD34+ selection results are shown in Table 1 . More than 4 X lo6 CD34' celldkg recipient body weight remained after immunomagnetic selection of CD34+ cells, which were cryopreserved for transplant. Data for CD3+ and natural killer (NK) cells were available for collections from donor B and showed a 99.99% (4-log) depletion for both cell types after CD34+ selection. The total of CD3+ cells infused with the enriched CD34+ cells to patient B was 0.3 X l v k g recipient body weight. Precise CD3' and NK cell data were not available for patient A's graft, but approximately 3 X lo5 CD3' cellskg recipient body weight were infused.
Engraftment of both patients was as rapid as is usually observed when using unmanipulated PBPCs in allogeneic or syngeneic transwith no more toxicity than the former. Engraftment has been complete and sustained in both patients (273 and 126 days posttransplant, respectively, as of this writing). (Table 2 with patient and donor characteristics). Both patients were discharged from the hospital within 14 days of transplant. DNA fingerprinting using PCR 2053 analysis of short tandem repeat^^.^ showed complete donor chimerism in both patients by days 14 and 9, respectively. Both patients developed acute GVHD. Patient A had grade 2 acute GVHD with skin and upper gastrointestinal tract involvement proven by tissue biopsy, and patient B had grade l skin acute GVHD. Both patients responded to steroid therapy. Both patients have achieved complete remission of their lymphomas as determined by full restaging, including BM examination. Patient A had BCL-2 gene rearrangement detectable in his marrow by polymerase chain reaction before transplant, however this marker was no longer detectable 67 days posttransplant.
COMMENTARY
Recent reports support the conclusion that unmanipulated PBPC from HLA-matched allogeneic donors mobilized with cytokines will provide sustained engraftment after tran~plantation.'.~' This is one of the first reports of successful allogeneic transplants in humans that has used only CD34+ cell-enriched PBPCs from cytokine-mobilized donors. PBPC mobilization from both donors was less than that achieved with normal donors in our previous study.' We were not able to obtain our target dose of CD34+ cells (minimum, 4.0 X lo6 kg recipient body weight) with one to two leukaphereses. In both donors a minimum of four leukapheresis procedures were required. However, 4.0 X lo6 CD34+ cellskg may be more than is absolutely necessary for engraftment. This determination will require further study. Also, with the increased number of aphereses required, Tcell depletion in absolute numbers becomes more difficult as the number before positive selection becomes increasingly large. Better methods of mobilization would improve the absolute CD34+ cell number, reduce the number of aphereses required, and lower the absolute number of T cells in the final graft after selection. We are currently studying different schedules of G-CSF and GM-CSF administration, including the sequential use of GM-CSF and G-CSF in normal volunteers for mobilization for apheresis and CD34+ selection.8 Large volume apheresis (215 L blood processing) could also reduce the number of aphereses necessary, with associated cost savings. The combination of GM-CSF and G-CSF was reasonably well tolerated by the donors, who were highly motivated to complete the schedule. There did not appear to be any unexpected toxicity associated with cytokine mobilization, which was consistent with our previous experience with normal donors.' Venous access was a problem with donor B, and necessitated temporary placement of a central venous apheresis catheter. Although they received T-cell-depleted grafts and were immunosuppressed with cyclosporine, both patients had mild (grade l) or moderate (grade 2) acute GVHD. However, it has been shown that as few as 1 X 10' donor T cellskg recipient body weight in the marrow graft in patients receiving a short course of cyclosporine posttransplant is sufficient to cause grade 1 or 2 acute GVHD.y It is uncertain at this time whether CD34' positive selection is comparable with other forms of T-cell depletion (TCD) in preventing GVHD. Although it has been postulated from animal studies that accessory cells may be required to facilitate engraftment"' and also to suppress GVHD," it would appear that with an adequate conditioning regimen, allogeneic transplantation with enriched CD34' PBSCs from fully matched sibling cytokine-mobilized donors is both feasible and safe. Depletion of NK cells may be disadvantageous because NK cells may contribute to graft-versus-leukemia effects, however the overall importance of this effect remains unclear" Finally, CD34' PBPC selection may not only reduce the incidence and severity of GVHD, but may be useful for matched unrelated donor transplants and in the future for other types of graft engineering including gene transduction and adoptive immunotherapy with selective donor T-cell expansion and infusion. Further study is required.
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